Principia Biopharma Inc. Common Stock
PRNB
PRNB was delisted on the 25th of September, 2020.
53 hedge funds and large institutions have $534M invested in Principia Biopharma Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 14 increasing their positions, 13 reducing their positions, and 11 closing their positions.
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
18% more funds holding
Funds holding: 45 → 53 (+8)
15% more capital invested
Capital invested by funds: $463M → $534M (+$71M)
8% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$11.2M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$10.3M |
| 3 |
BlackRock
New York
|
+$7.55M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$5.8M |
| 5 |
JP Morgan Chase
New York
|
+$3.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.38M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.92M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$2.41M |
| 4 |
RI
RTW Investments
New York
|
-$2.28M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
-$2.19M |
PRNB Hedge Fund Activity: Q4 2018 in Review
53 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Principia Biopharma Inc. Common Stock (PRNB) for Q4 2018, worth a combined $534M — up 15% from $463M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new PRNB positions and 11 closed out — a net gain of 8 holders — while 14 added to existing stakes and 13 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $11.2M. The largest seller was Millennium Management, cutting an estimated $3.38M.
- 53 institutional investors held Principia Biopharma Inc. Common Stock (PRNB) as of Q4 2018, up from 45 in Q3 2018.
- Funds reported $534M of Principia Biopharma Inc. Common Stock stock for Q4 2018, up 15% quarter-over-quarter.
- 19 funds opened new Principia Biopharma Inc. Common Stock positions in Q4 2018 and 11 closed out, a net change of +8 holders.
- The largest Principia Biopharma Inc. Common Stock buyer in Q4 2018 was Fidelity Investments, an estimated $11.2M added.
- The largest Principia Biopharma Inc. Common Stock seller in Q4 2018 was Millennium Management, an estimated $3.38M sold.
Based on aggregated 13F filings for Q4 2018.